GlassScriptPhysician profile
David Bernard Miklos
NPI 1982751053
$90,232.48
in general payments reported to CMS, 2019-2025
23 companies · $12K in 2025
The $12K reported for 2025 was more than what 79% of Hematology (Internal Medicine) providers received nationally (typical 2025 total: $1,177).
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31K · 2020: $19K · 2021: $4,300 · 2022: $1,073 · 2023: $18K · 2024: $5,466 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $19K · Consulting Fee: $12K · Food and Beverage: $3,573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $19,278.44 |
| Consulting Fee | $12,340.00 |
| Food and Beverage | $3,572.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $34,982.00 | 2019-2025 | Yescarta |
| Gilead Sciences, INC. | $17,350.44 | 2023-2025 | Yescarta |
| Adaptive Biotechnologies Corporation | $10,454.86 | 2019-2025 | Clonoseq |
| Eusa Pharma (US) LLC | $6,204.57 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $5,252.50 | 2024-2025 | |
| Celgene Corporation | $5,037.32 | 2020-2025 | Breyanzi |
| Takeda Pharmaceuticals U.S.A., INC. | $2,640.00 | 2020 | |
| Janssen Global Services, LLC | $2,480.00 | 2020 | |
| Novartis Pharma Ag | $1,811.01 | 2023-2024 | Kymriah |
| Janssen Scientific Affairs, LLC | $1,240.00 | 2020 | |
| Eli Lilly and Company | $1,000.00 | 2025 | |
| Novartis Pharmaceuticals Corporation | $703.01 | 2019-2025 | |
| Regeneron Pharmaceuticals, INC. | $233.96 | 2022 | |
| Sobi, INC | $189.91 | 2024-2025 | |
| Stryker Corporation | $182.08 | 2023-2025 | Citrefix, Ortholoc 3di, Sonicanchor |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $181.11 | 2025 | Brukinsa |
| Astrazeneca Pharmaceuticals LP | $96.32 | 2023 | |
| Janssen Biotech, INC. | $79.33 | 2025 | Talvey, Tecvayli, Darzalex |
| Iovance Biotherapeutics, INC. | $47.54 | 2024 | Amtagvi |
| Csl Behring | $24.97 | 2021 | |
| Genetix Biotherapeutics INC | $23.01 | 2025 | Lyfgenia |
| Amgen INC. | $18.54 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Miklos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.